Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Continuous blood glucose monitoring trial enrolment completed

GlySure : 04 November, 2013  (Company News)
Thirty intensive care unit patients will take part in trial of continuous blood glucose monitoring system from GlySure
Continuous blood glucose monitoring trial enrolment completed


GlySure has completed patient enrolment for the multicentre CE Mark trial of its in-hospital continuous blood glucose monitoring (CBGM) system. The trial, led by Principal Investigator Dr Krishna Prasad, comprised 30 post surgery cardiac intensive care unit patients.



Over the past two years, Dr Prasad has tested the GlySure CBGM system in over 160 intensive care unit (ICU) patients demonstrating high levels of accuracy and repeatability for up to five days of continuous monitoring. He comments on this next stage of the technology’s development.



“For over a decade, the clinical community has been seeking a way to tightly control glucose levels in ICU patients that enables them to perform this function with accuracy, reliability and efficiency,” said Dr Prasad. “Our trials to date indicate that GlySure’s technology can address the decade-long demand for better ICU glycemic control and I am excited to embark on this next stage of its testing.”



“We’ve made tremendous progress in 2013 with the advancements in our technology, expansion of intellectual property and completion of enrolment in our CE Mark trial,” said GlySure CEO Chris Jones. “The CE Mark trial is another significant milestone in our company’s development. We look forward to being able to bring this product to market and engaging with European clinicians to deliver simple, accurate and effective glycemic control for ICU patients.”


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo